Paul K. Audhya Sells 3,125 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 3,125 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the sale, the insider now owns 100,334 shares of the company’s stock, valued at approximately $985,279.88. This represents a 3.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV opened at $10.64 on Friday. The firm has a market cap of $525.83 million, a PE ratio of -2.92 and a beta of 0.85. The firm has a 50 day simple moving average of $8.84 and a 200-day simple moving average of $10.43. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. As a group, sell-side analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on KALV shares. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price on the stock. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Finally, Bank of America assumed coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $23.80.

Institutional Trading of KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aquatic Capital Management LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 4th quarter worth about $44,000. Tower Research Capital LLC TRC lifted its position in KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 5,502 shares in the last quarter. Legal & General Group Plc grew its stake in KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 1,494 shares during the period. Martin Worley Group purchased a new stake in KalVista Pharmaceuticals during the fourth quarter worth approximately $86,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 2,043 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).